For research and educational purposes only. Not intended for human consumption.
Orforglipron
Extensively Studied- •Phase 3 ATTAIN trials ongoing
- •14.7% weight loss efficacy
- •First oral non-peptide GLP-1 agonist
Oral Small-Molecule GLP-1 Receptor Agonist | Weight Loss & Diabetes
Overview
What is Orforglipron?
Orforglipron is a novel oral non-peptide GLP-1 receptor agonist in Phase 3 clinical trials for obesity and type 2 diabetes. Unlike injectable GLP-1 agonists, it can be taken as a daily pill without food restrictions, offering similar weight loss efficacy (up to 14.7%) with greater convenience. Developed by Eli Lilly as a potential game-changer in obesity treatment.
Key Benefits
Oral administration (no injections), no food restrictions, comparable efficacy to injectable GLP-1s, daily dosing convenience, room temperature storage.
Mechanism of Action
Orforglipron is a small molecule that activates GLP-1 receptors similarly to endogenous GLP-1, reducing appetite, increasing satiety, and improving insulin secretion in a glucose-dependent manner.
Molecular Information
Pharmacokinetics
Research Indications
Obesity Without Diabetes
Up to 14.7% weight loss at 36 weeks in Phase 2 trials.
Obesity With Type 2 Diabetes
Significant weight loss in diabetic patients.
Cardiometabolic Improvement
Improvements in cardiovascular risk factors.
Research Protocols
Disclaimer: Orforglipron is in Phase 3 clinical trials and not yet FDA approved. Protocols are based on clinical trial data.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Obesity (Phase 3 dose) | 36-45mg daily | Once daily | Oral |
| Diabetes (Phase 3 dose) | 36-45mg daily | Once daily | Oral |
| Dose Escalation | 3mg → 6mg → 12mg → 24mg → 36mg → 45mg | Weekly increases | Oral |
Timing: Take at the same time each day. No food restrictions - can be taken with or without food.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
No reconstitution needed - oral tablet
Take at the same time each day
Can be taken with or without food
Swallow whole with water
Do not crush, split, or chew tablets
Store at room temperature
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Oral convenience
No injections required - daily tablet.
No food restrictions
Can be taken any time without fasting.
Not yet approved
Currently in Phase 3 trials - FDA approval pending.
GI side effects
Nausea and vomiting common during dose escalation.
What to Expect
- •Week 1-2: GI adaptation, appetite suppression begins
- •Week 4-8: Noticeable weight loss (2-5%)
- •Week 12-24: Significant weight loss (8-12%)
- •Week 24-36: Maximum weight loss achieved (up to 14.7%)
Side Effects & Safety
Side Effects
- •Most common: nausea (40-50%), vomiting, diarrhea
- •GI side effects typically mild-moderate and diminish over time
- •Dose escalation protocol minimizes side effects
- •Similar safety profile to injectable GLP-1s
- •Not recommended during pregnancy
When to Stop
- •Severe persistent nausea/vomiting
- •Signs of pancreatitis
- •Allergic reactions
- •As directed by healthcare provider
References
2 StudiesACHIEVE-1 Phase 2 Obesity Trial
Human | Up to 45mg daily | 36 weeks | 14.7% weight loss at highest dose
Demonstrated oral GLP-1 can achieve weight loss comparable to injectables.
ACHIEVE-2 Phase 2 Diabetes Trial
Human | Various doses | 26 weeks | Significant HbA1c reduction
Showed glycemic efficacy in type 2 diabetes patients.
Quick Start Guide
Research Disclaimer
Orforglipron is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Orforglipron must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Orforglipron for any purpose. Consult qualified professionals for any research applications.